tiprankstipranks
Trending News
More News >
BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
Germany Market

BioMarin Pharmaceutical (BM8) Ratios

Compare
1 Followers

BioMarin Pharmaceutical Ratios

DE:BM8's free cash flow for Q4 2025 was $0.66. For the 2025 fiscal year, DE:BM8's free cash flow was decreased by $ and operating cash flow was $-0.03. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
5.21 5.21 5.33 2.51 4.67
Quick Ratio
3.50 3.50 3.29 1.57 3.15
Cash Ratio
1.73 1.73 1.55 0.64 1.23
Solvency Ratio
0.28 0.28 0.39 0.14 0.14
Operating Cash Flow Ratio
1.09 1.09 0.94 0.14 0.30
Short-Term Operating Cash Flow Coverage
95.34 95.34 24.83 0.32 0.00
Net Current Asset Value
$ 2.45B$ 2.45B$ 1.90B$ 1.07B$ 979.54M
Leverage Ratios
Debt-to-Assets Ratio
0.08 0.08 0.09 0.16 0.17
Debt-to-Equity Ratio
0.11 0.11 0.11 0.22 0.24
Debt-to-Capital Ratio
0.10 0.10 0.10 0.18 0.19
Long-Term Debt-to-Capital Ratio
0.09 0.09 0.10 0.11 0.19
Financial Leverage Ratio
1.25 1.25 1.24 1.38 1.38
Debt Service Coverage Ratio
22.43 22.43 14.99 0.56 16.11
Interest Coverage Ratio
48.95 48.95 38.23 10.72 10.08
Debt to Market Cap
0.06 0.05 0.05 0.06 0.06
Interest Debt Per Share
3.41 3.41 3.48 5.93 5.99
Net Debt to EBITDA
-1.17 -1.17 -0.45 1.11 1.39
Profitability Margins
Gross Profit Margin
77.13%77.13%79.67%78.01%76.00%
EBIT Margin
15.32%15.32%19.42%8.37%7.80%
EBITDA Margin
17.79%17.79%22.79%12.68%12.66%
Operating Profit Margin
16.56%16.56%16.97%7.68%7.68%
Pretax Profit Margin
14.98%14.98%18.98%7.79%7.14%
Net Profit Margin
10.83%10.83%14.96%6.93%6.75%
Continuous Operations Profit Margin
10.83%10.83%14.96%6.93%6.75%
Net Income Per EBT
72.31%72.31%78.79%88.91%94.64%
EBT Per EBIT
90.44%90.44%111.89%101.50%92.92%
Return on Assets (ROA)
4.59%4.59%6.11%2.45%2.22%
Return on Equity (ROE)
5.82%5.73%7.54%3.39%3.08%
Return on Capital Employed (ROCE)
7.81%7.81%7.59%3.28%2.78%
Return on Invested Capital (ROIC)
5.64%5.64%5.96%2.68%2.63%
Return on Tangible Assets
4.86%4.86%6.53%2.64%2.42%
Earnings Yield
3.28%3.06%3.42%0.93%0.74%
Efficiency Ratios
Receivables Turnover
3.55 3.55 4.32 3.82 4.54
Payables Turnover
2.36 2.36 2.46 1.69 2.18
Inventory Turnover
0.57 0.57 0.47 0.48 0.56
Fixed Asset Turnover
3.38 3.38 2.74 2.27 1.95
Asset Turnover
0.42 0.42 0.41 0.35 0.33
Working Capital Turnover Ratio
1.03 1.11 1.30 1.23 1.08
Cash Conversion Cycle
591.40 591.40 711.80 638.71 561.30
Days of Sales Outstanding
102.91 102.91 84.48 95.61 80.33
Days of Inventory Outstanding
643.42 643.42 775.41 759.54 648.76
Days of Payables Outstanding
154.93 154.93 148.08 216.44 167.79
Operating Cycle
746.33 746.33 859.89 855.15 729.09
Cash Flow Ratios
Operating Cash Flow Per Share
4.32 4.32 3.01 0.85 0.95
Free Cash Flow Per Share
3.78 3.78 2.50 0.33 0.30
CapEx Per Share
0.54 0.54 0.51 0.51 0.65
Free Cash Flow to Operating Cash Flow
0.88 0.88 0.83 0.39 0.31
Dividend Paid and CapEx Coverage Ratio
8.04 8.04 5.88 1.65 1.45
Capital Expenditure Coverage Ratio
8.04 8.04 5.88 1.65 1.45
Operating Cash Flow Coverage Ratio
1.29 1.29 0.88 0.15 0.16
Operating Cash Flow to Sales Ratio
0.26 0.26 0.20 0.07 0.08
Free Cash Flow Yield
6.80%6.36%3.81%0.35%0.29%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
30.47 32.67 29.26 108.03 135.44
Price-to-Sales (P/S) Ratio
3.31 3.54 4.38 7.49 9.15
Price-to-Book (P/B) Ratio
1.75 1.87 2.21 3.66 4.17
Price-to-Free Cash Flow (P/FCF) Ratio
14.70 15.72 26.27 289.46 348.96
Price-to-Operating Cash Flow Ratio
12.84 13.77 21.80 113.72 109.00
Price-to-Earnings Growth (PEG) Ratio
-0.92 -1.71 0.19 6.32 -0.43
Price-to-Fair Value
1.75 1.87 2.21 3.66 4.17
Enterprise Value Multiple
17.44 18.73 18.75 60.15 73.64
Enterprise Value
9.99B 10.73B 12.20B 18.45B 19.54B
EV to EBITDA
17.43 18.73 18.75 60.15 73.64
EV to Sales
3.10 3.33 4.27 7.63 9.32
EV to Free Cash Flow
13.78 14.80 25.66 294.90 355.68
EV to Operating Cash Flow
12.06 12.96 21.29 115.86 111.10
Tangible Book Value Per Share
29.60 29.60 27.40 23.75 21.96
Shareholders’ Equity Per Share
31.74 31.74 29.77 26.36 24.85
Tax and Other Ratios
Effective Tax Rate
0.28 0.28 0.21 0.11 0.05
Revenue Per Share
16.80 16.80 15.02 12.88 11.31
Net Income Per Share
1.82 1.82 2.25 0.89 0.76
Tax Burden
0.72 0.72 0.79 0.89 0.95
Interest Burden
0.98 0.98 0.98 0.93 0.92
Research & Development to Revenue
0.29 0.29 0.26 0.31 0.31
SG&A to Revenue
0.36 0.36 0.19 0.17 0.18
Stock-Based Compensation to Revenue
0.06 0.06 0.07 0.09 0.09
Income Quality
1.15 2.37 1.34 0.95 1.24
Currency in USD